Neumora Therapeutics, Inc. financial data

Symbol
NMRA on Nasdaq
Location
490 Arsenal Way, Suite 200, Watertown, MA
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 920 % -42.3%
Debt-to-equity 17.5 % +158%
Return On Equity -114 % -54.6%
Return On Assets -96.9 % -40.5%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 167M shares +3.42%
Common Stock, Shares, Outstanding 162M shares +1.81%
Entity Public Float 824M USD
Common Stock, Value, Issued 16K USD 0%
Weighted Average Number of Shares Outstanding, Basic 162M shares +1.42%
Weighted Average Number of Shares Outstanding, Diluted 162M shares +1.42%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 177M USD -8.55%
General and Administrative Expense 63.3M USD +11.5%
Operating Income (Loss) -246M USD +21.9%
Nonoperating Income (Expense) 9.43M USD -55.7%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest -236M USD +21.7%
Income Tax Expense (Benefit) 0 USD -100%
Net Income (Loss) Attributable to Parent -236M USD +19.5%
Earnings Per Share, Basic -1 USD/shares -27.8%
Earnings Per Share, Diluted -1 USD/shares -27.8%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 129M USD -53.2%
Marketable Securities, Current 42.5M USD -35.3%
Assets, Current 177M USD -49.2%
Property, Plant and Equipment, Net 80K USD -93.8%
Operating Lease, Right-of-Use Asset 474K USD -82%
Other Assets, Noncurrent 197K USD
Assets 178M USD -49.6%
Accounts Payable, Current 549K USD -91%
Employee-related Liabilities, Current 8.86M USD +0.16%
Accrued Liabilities, Current 25M USD +9.77%
Liabilities, Current 25.8M USD -18.6%
Operating Lease, Liability, Noncurrent 267K USD
Liabilities 45.7M USD +43.6%
Accumulated Other Comprehensive Income (Loss), Net of Tax 9K USD -91.4%
Retained Earnings (Accumulated Deficit) -1.12B USD -26.6%
Stockholders' Equity Attributable to Parent 132M USD -58.8%
Liabilities and Equity 178M USD -49.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -59.4M USD -38.4%
Net Cash Provided by (Used in) Financing Activities 0 USD -100%
Net Cash Provided by (Used in) Investing Activities 44.2M USD
Common Stock, Shares Authorized 700M shares 0%
Common Stock, Shares, Issued 162M shares +1.81%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -15.3M USD +92%
Interest Paid, Excluding Capitalized Interest, Operating Activities 747K USD
Deferred Tax Assets, Valuation Allowance 264M USD +34%
Deferred Tax Assets, Gross 265M USD +33.3%
Operating Lease, Liability 5.23M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -236M USD +19.4%
Lessee, Operating Lease, Liability, to be Paid 1.89M USD -66.3%
Property, Plant and Equipment, Gross 3.19M USD -1.12%
Operating Lease, Liability, Current 256K USD -90.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.89M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 1.89M USD -49.1%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 39K USD -89.7%
Deferred Tax Assets, Operating Loss Carryforwards 112M USD +41.7%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 50M shares
Unrecognized Tax Benefits 9.68M USD +11.7%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 157K USD -0.63%
Deferred Tax Assets, Net of Valuation Allowance 538K USD -64.1%
Share-based Payment Arrangement, Expense 32.4M USD -10.4%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%